Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Novo Nordisk accused Hims of [failing] to adhere to the law which prohibits mass sales of compounded drugs under the false guise of personalization and [] disseminating deceptive marketing that put patient safety at risk. In August 2025, Novo Nordisk lowered guidance during its earnings report and partly blamed the production of compounded semaglutide for the reduction
Glickman says
doi: 10.1016/j.bodyim.2025.101890, 94 MartinC
An investigational GLP-1 pill from Eli Lilly helped diabetes patients lower their blood sugar and weight more than an oral version of Ozempic sold by Novo Nordisk, results that support the efficacy of Lillys medicine as the company prepares to submit it to regulators
GLP-1 Prescribing Is Rising But Not Equally Across Populations November 11, 2025 Summary: Prescriptions for GLP-1 medications have increased sharply for obesity, type 2 diabetes, and people with both conditions
US$ 23.41
US$ 22.48
US$ 26.43
US$ 21.62
US$ 24.52
US$ 28.36
US$ 24.93
